Biomarkers Across Neurodegenerative Diseases
The Michael J. Fox Foundation, the Alzheimer’s Association, Alzheimer’s Research UK, and the Weston Brain Institute announce a global request for applictions. The main objective of the Biomarkers Across Neurodegenerative Diseases (BAND) program is to stimulate analyses across Alzheimer’s, Parkinson’s and other neurodegenerative diseases to increase understanding of pathogenic similarities and differences. Ultimately, the goal of this program is to translate the research into strategies to increase understanding of the similarities or differences across and between neurodegenerative diseases to help stratify populations and develop possible diagnostic tools or treatments.
The intent of this RFA is to analyze across existing data; biological samples are not available for use under this RFA. Funding from this program may support but is not limited to projects around innovative data models, biomarker discovery, assay standardization, genetic profiling, cross-disease or longitudinal analyses of existing data, or imaging development.
Learn more on the program at www.alz.org/BAND.
The partners held a webinar on August 20, 2018 to clarify and explain the goals of this funding initiative and answer applicant questions. Watch the webinar.
Full Proposal Invitations:
Full Proposals Due (by invite only):
Anticipated Award Announcement:
September 10, 2018
October 22, 2018
December 1, 2018
Applicants may request up to two years and $150,000 in total costs, inclusive of both direct and indirect costs. Exceptions for particularly unique projects or projects that span the globe will be considered, but requests that exceed $150,000 must be well justified in the application.
For more information, visit the Administrative Guidelines page.
Read the full RFA information at www.alz.org/BAND
Submit a Letter of Intent at https://proposalcentral.altum.com/.